Insilico 3D Structure Modeling and Docking to Find Potent Inhibitors for Thrombocytopenia

Authors

  • Pranati Swain Bioinformatics, Orissa University of Agriculture and Technology, Orissa, India
  • Jasnaik D. School of Biotechnology and Bioinformatics, DY Patil University, Maharashtra, India

DOI:

https://doi.org/10.37591/(rrjobi).v1i3.369

Abstract

Lots of people are getting affected by various kinds of auto-immune disease in their day to day life and thrombocytopenia is one of them, which occurs due to lack of thrombocytes or platelets. Various kinds of vaccines, drugs are used to stop the disease, but the effect varies from person to person depending upon the immune system. In thrombocytopenia disease the integrin beta protein of human affects the person’s own immune system leading in the less production of thrombocytes. Here the main objective of the study is to analyse the interaction between the disease stimulating proteins and the ligands or drugs bind to the protein at its active site. The structural prediction along with the stereo-chemical evaluation of protein helped to understand the function of the protein. The active sites of protein show the ligand binding regions. 14 different drugs were considered for the study. Out of which AC1NS627 drug showed best interaction with the protein as its binding perfectly at the active site of the protein. So from the study, we can conclude that AC1NS627 is the better drug which can be used for inhibiting the activity of integrin beta protein.

 

Keywords: In silico homology modeling, thrombocytopenia, molecular docking

 

Downloads

Published

2019-03-07

Issue

Vol. 1 No. 3 (2014)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.